samedan logo
 
 
spacer
home > pmps > spring 2004 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

Spring came early this year for many regions of Europe and with it the first signs of a tentative recovery for the life science sector of industry. Then, just as the first green shoots pushed above ground or tree buds burst into blossom, a sharp frost or a howling gale reminded us that winter was not yet over. As I write from high up in the Swiss Alps, snow is falling heavily but the alpine plants appear well-adapted to these extremes of climate.

Media groups, including the publisher of PMPS, Samedan Ltd, are an early bellweather of the

sector's fortunes. Recalling that media organisations were the first to suffer at the signs of a long, hard winter as revenues took a nosedive, it's heartening to see an upturn in activity this year. The news from Bio/PharMOS, the early spring event in Monte Carlo which took place in March, was also very positive, with most exhibitors reporting a substantially higher level of enquiries and leads for contract manufacturing business, especially for secondary processing and packaging. The trend for outsourcing is, however, patchy and precarious. For example, the demand for production and development services in pharma, helped along to some extent by the booming generics market, has not been matched by the biotech sector.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Editor of PMPS, Patricia Lobo rounds up current issues impacting on development and manufacturing in biotech and pharma.
spacer
Patricia Lobo
spacer
spacer
spacer
Lucy Kearney
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical Researcher of the Year - The Americas 2021 winners announced

The winners of the 2021 Clinical Researcher of the Years The Americas competition have been announced, with the exceptional talent of clinical researchers across the Americas recognised during a live virtual awards ceremony.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement